Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study - Summary - MDSpire
Advertisement
Aripiprazole as second-line pharmacotherapy for a heterogeneous cohort of refractory functional dizziness disorders: a pilot preliminary retrospective study
To evaluate the preliminary efficacy and tolerability of aripiprazole as second-line pharmacotherapy in patients with refractory functional dizziness disorders, including PPPD and other related conditions.
Key Findings:
75.0% of patients (12 of 16) showed CGI-I response indicating improvement.
Four patients were non-responders, and one discontinued due to extrapyramidal side effects.
Improvements were noted in DHI and NPQ scores among evaluable patients (n=4-5), while foam posturography showed no significant changes.
Interpretation:
Aripiprazole demonstrated promising preliminary efficacy as a second-line treatment for refractory functional dizziness disorders, potentially addressing symptoms inadequately managed by serotonergic agents, possibly due to its multimodal action.
Limitations:
Small sample size.
Uncontrolled study design affecting reliability.
Conclusion:
These findings should be considered hypothesis-generating, warranting further prospective controlled studies.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
